Astellas Pharma and VIR Biotechnology announced a collaboration to develop a PSMA-targeted T-cell engager.
1 report, 1 independent
Updated Oct 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Astellas Pharma and VIR Biotechnology announced a collaboration to develop a PSMA-targeted T-cell engager.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Astellas Pharma
company
Nothing else this week.
-
VIR Biotechnology
biotech company